ResMed Inc (RMD)
Return on equity (ROE)
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 1,313,254 | 1,248,705 | 1,112,883 | 1,020,950 | 958,378 | 890,386 | 906,500 | 897,556 | 862,953 | 809,465 | 786,302 | 779,437 | 779,474 | 521,981 | 499,744 | 474,503 | 457,240 | 698,858 | 679,898 | 621,674 |
| Total stockholders’ equity | US$ in thousands | 5,546,130 | 5,253,010 | 5,195,030 | 4,864,040 | 4,629,920 | 4,481,850 | 4,250,380 | 4,129,900 | 3,932,510 | 3,738,130 | 3,432,890 | 3,360,750 | 3,278,800 | 3,145,840 | 3,026,050 | 2,885,680 | 2,709,230 | 2,864,980 | 2,678,860 | 2,497,030 |
| ROE | 23.68% | 23.77% | 21.42% | 20.99% | 20.70% | 19.87% | 21.33% | 21.73% | 21.94% | 21.65% | 22.90% | 23.19% | 23.77% | 16.59% | 16.51% | 16.44% | 16.88% | 24.39% | 25.38% | 24.90% |
March 31, 2025 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,313,254K ÷ $5,546,130K
= 23.68%
The analysis of ResMed Inc.'s return on equity (ROE) over the period from June 2020 through March 2025 reveals notable fluctuations with an overall tendency toward stabilization at higher levels following periods of decline.
Initially, the company's ROE was robust at 24.90% as of June 30, 2020, and experienced a slight increase to 25.38% by September 30, 2020. However, a subsequent decline was observed, with ROE decreasing to 24.39% by December 31, 2020.
In the first quarter of 2021, a significant decline occurred, with ROE dropping to 16.88% in March 2021, and maintaining relatively similar levels through June (16.44%) and September (16.51%) of 2021. This period indicates a reduction in the company's efficiency in generating returns on shareholders' equity, possibly reflecting operational, strategic, or market-related challenges.
From December 31, 2021, onward, a recovery trend emerged. ROE increased to 23.77% by March 31, 2022, and remained in the low-to-mid 23% range through June 2022 (23.19%) and September 2022 (22.90%), before declining slightly to 21.65% by December 2022. Through 2023, the ROE stabilized around the 21.94% level in March and experienced minor fluctuations, ending December 2023 at 19.87%.
In the subsequent quarters, the ROE demonstrated signs of recovery once again, reaching 20.70% in March 2024 and continuing upward to 21.42% by September 2024. By December 2024, the ROE rose to 23.77%, surpassing previous peak levels, and maintained a near similar level at 23.68% in March 2025.
Overall, the ROE for ResMed Inc. exhibits periods of both decline and recovery, indicative of cyclical operational or market factors influencing profitability and shareholders' equity returns. The trend suggests resilience with an upward trajectory toward the latter part of the observed period, reaching levels comparable to or exceeding pre-2021 peaks.
Peer comparison
Mar 31, 2025